Global Contract Development and Manufacturing Organization (CDMO) Market: By Service Type CMO: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing; By Research Phase CRO; By Therapeutic Area; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032

 1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Contract Development and Manufacturing Organisation (CDMO) Market Overview 
    3.1    Global Contract Development and Manufacturing Organisation (CDMO) Market Historical Value (2017-2023) 
    3.2    Global Contract Development and Manufacturing Organisation (CDMO) Market Forecast Value (2024-203)
4    Global Contract Development and Manufacturing Organisation (CDMO) Market Landscape*
    4.1    Contract Development and Manufacturing Organisation (CDMO): Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Contract Development and Manufacturing Organisation (CDMO): Service Landscape
        4.2.1    Analysis by Service Type CMO
        4.2.2    Analysis by Therapeutic Area
        4.2.3    Analysis by Research Phase CRO
5    Global Contract Development and Manufacturing Organisation (CDMO) Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Global Contract Development and Manufacturing Organisation (CDMO) Market Segmentation (2017-2032)
    6.1    Global Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
        6.1.1    Market Overview
        6.1.2    Active Pharmaceutical Ingredient (API) Manufacturing
            6.1.2.1    Small Molecule
            6.1.2.2    Large Molecule
            6.1.2.3    High Potency (HPAPI)
        6.1.3    Finished Dosage Formulation (FDF) Development and Manufacturing
            6.1.3.1    Solid Dose Formulation 
            6.1.3.2    Liquid Dose Formulation
            6.1.3.3    Injectable Dose Formulation
        6.1.4    Secondary Packaging Services
    6.2    Global Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
        6.2.1    Pre-clinical
        6.2.2    Phase I
        6.2.3    Phase II
        6.2.4    Phase III
        6.2.5    Phase IV
    6.3    Global Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Therapeutic Area
        6.3.1    Market Overview
        6.3.2    Oncological Diseases
        6.3.3    Cardiovascular Diseases
        6.3.4    Infectious Diseases
        6.3.5    Others
    6.4    Global Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Region
        6.4.1    North America
        6.4.2    Europe
        6.4.3    Asia Pacific
        6.4.4    Latin America 
        6.4.5    Middle East and Africa
7    North America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
    7.1    North America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
        7.1.1    Market Overview
        7.1.2    Active Pharmaceutical Ingredient (API) Manufacturing
            7.1.2.1    Small Molecule
            7.1.2.2    Large Molecule
            7.1.2.3    High Potency (HPAPI)
        7.1.3    Finished Dosage Formulation (FDF) Development and Manufacturing
            7.1.3.1    Solid Dose Formulation
            7.1.3.2    Liquid Dose Formulation
            7.1.3.3    Injectable Dose Formulation
        7.1.4    Secondary Packaging Services
    7.2    North America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
        7.2.1    Pre-clinical
        7.2.2    Phase I
        7.2.3    Phase II
        7.2.4    Phase III
        7.2.5    Phase IV
    7.3    North America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) 
    8.1    Europe Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
        8.1.1    Market Overview
        8.1.2    Active Pharmaceutical Ingredient (API) Manufacturing
            8.1.2.1    Small Molecule
            8.1.2.2    Large Molecule
            8.1.2.3    High Potency (HPAPI)
        8.1.3    Finished Dosage Formulation (FDF) Development and Manufacturing
            8.1.3.1    Solid Dose Formulation (Tablets)
            8.1.3.2    Liquid Dose Formulation
            8.1.3.3    Injectable Dose Formulation
        8.1.4    Secondary Packaging Services
    8.2    Europe Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
        8.2.1    Pre-clinical
        8.2.2    Phase I
        8.2.3    Phase II
        8.2.4    Phase III
        8.2.5    Phase IV
    8.3    Europe Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
    9.1    Asia Pacific Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
        9.1.1    Market Overview
        9.1.2    Active Pharmaceutical Ingredient (API) Manufacturing
            9.1.2.1    Small Molecule
            9.1.2.2    Large Molecule
            9.1.2.3    High Potency (HPAPI)
        9.1.3    Finished Dosage Formulation (FDF) Development and Manufacturing
            9.1.3.1    Solid Dose Formulation (Tablets)
            9.1.3.2    Liquid Dose Formulation
            9.1.3.3    Injectable Dose Formulation
        9.1.4    Secondary Packaging Services
    9.2    Asia Pacific Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
        9.2.1    Pre-clinical
        9.2.2    Phase I
        9.2.3    Phase II
        9.2.4    Phase III
        9.2.5    Phase IV
    9.3    Asia Pacific Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    Australia
        9.3.5    ASEAN
        9.3.6    Others
10    Latin America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
    10.1    Latin America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
        10.1.1    Market Overview
        10.1.2    Active Pharmaceutical Ingredient (API) Manufacturing
            10.1.2.1    Small Molecule
            10.1.2.2    Large Molecule
            10.1.2.3    High Potency (HPAPI)
        10.1.3    Finished Dosage Formulation (FDF) Development and Manufacturing
            10.1.3.1    Solid Dose Formulation (Tablets)
            10.1.3.2    Liquid Dose Formulation
            10.1.3.3    Injectable Dose Formulation
        10.1.4    Secondary Packaging Services
    10.2    Latin America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
        10.2.1    Pre-clinical
        10.2.2    Phase I
        10.2.3    Phase II
        10.2.4    Phase III
        10.2.5    Phase IV
    10.3    Latin America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
    11.1    Middle East and Africa Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
        11.1.1    Market Overview
        11.1.2    Active Pharmaceutical Ingredient (API) Manufacturing
            11.1.2.1    Small Molecule
            11.1.2.2    Large Molecule
            11.1.2.3    High Potency (HPAPI)
        11.1.3    Finished Dosage Formulation (FDF) Development and Manufacturing
            11.1.3.1    Solid Dose Formulation (Tablets)
            11.1.3.2    Liquid Dose Formulation
            11.1.3.3    Injectable Dose Formulation
        11.1.4    Secondary Packaging Services
    11.2    Middle East and Africa Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
        11.2.1    Pre-clinical
        11.2.2    Phase I
        11.2.3    Phase II
        11.2.4    Phase III
        11.2.5    Phase IV
    11.3    Middle East and Africa Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
13    Patent Analysis
    13.1    Analysis by Type of Patent
    13.2    Analysis by Publication year
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Patent Age
    13.5    Analysis by CPC Analysis
    13.6    Analysis by Patent Valuation 
    13.7    Analysis by Key Players
14    Grants Analysis
    14.1    Analysis by year
    14.2    Analysis by Amount Awarded
    14.3    Analysis by Issuing Authority
    14.4    Analysis by Grant Application
    14.5    Analysis by Funding Institute
    14.6    Analysis by NIH Departments
    14.7    Analysis by Recipient Organization 
15    Funding and Investment Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Supplier Landscape
    17.1    Catalant Inc.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications 
    17.2    Baxter Biopharma Solutions (Baxter International Inc.) 
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Vetter Pharma-Fertigung GmbH & Co. KG 
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Recipharm AB
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Albany Moleculer Research Inc. (AMRI)
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Thermo Fisher Scientific
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Boehringer Ingelheim Group
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Pfizer Inc.
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    NextPharma Technologies
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Jubilant Pharmova Ltd 
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Famar SA
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Lonza Group
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    TapeMark
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Novotech Pty Ltd
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    ARX LLC
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
    17.16    Aenova Holding GmBH
        17.16.1    Financial Analysis
        17.16.2    Product Portfolio
        17.16.3    Demographic Reach and Achievements
        17.16.4    Mergers and Acquisitions
        17.16.5    Certifications
    17.17    Tesa Labtec GmbH (TESA SE) 
        17.17.1    Financial Analysis
        17.17.2    Product Portfolio
        17.17.3    Demographic Reach and Achievements
        17.17.4    Mergers and Acquisitions
        17.17.5    Certifications
    17.18    CMIC Holdings Company Ltd
        17.18.1    Financial Analysis
        17.18.2    Product Portfolio
        17.18.3    Demographic Reach and Achievements
        17.18.4    Mergers and Acquisitions
        17.18.5    Certifications
    17.19    Syneos Health Inc.
        17.19.1    Financial Analysis
        17.19.2    Product Portfolio
        17.19.3    Demographic Reach and Achievements
        17.19.4    Mergers and Acquisitions
        17.19.5    Certifications
    17.20    LabCorp Drug Development
        17.20.1    Financial Analysis
        17.20.2    Product Portfolio
        17.20.3    Demographic Reach and Achievements
        17.20.4    Mergers and Acquisitions
        17.20.5    Certifications
18    Key Opinion Leaders (KOL) Insights (Additional Insight)
19    Company Competitiveness Analysis (Additional Insight)
    19.1    Very Small Companies
    19.2    Small Companies
    19.3    Mid-Sized Companies
    19.4    Large Companies
    19.5    Very Large Companies
20    Payment Methods (Additional Insight)
    20.1    Government Funded
    20.2    Private Insurance
    20.3    Out-of-Pocket

 
*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.